AdvanCell, a clinical-stage radiopharmaceutical company, has successfully raised $315 million in a Series D financing round, aimed at advancing its lead prostate cancer treatment into phase 3 trials.
This oversubscribed round, led by Ally Bridge Group and Alpha Wave, will support the development of ADVC001, a PSMA-targeted radioligand therapy utilizing lead-212. The treatment has shown promising results in phase 2 trials for metastatic prostate cancer, achieving a 100% overall response rate without significant toxicity issues. AdvanCell is among several biotech firms focused on targeted alpha therapies (TATs), which aim to deliver localized radiation while minimizing damage to surrounding healthy tissue.
Currently, Bayer's Xofigo is the only approved TAT for metastatic castration-resistant prostate cancer, but its sales have declined due to safety concerns. Other companies in the TAT space include Orano Med and RadioMedix, among others. The new financing round also saw participation from notable investors like Bain Capital Life Sciences and Fidelity Management.
In addition to AdvanCell's success, other biotech firms have recently secured funding. Draig Therapeutics raised $65 million for neuropsychiatric disorder therapies, while Drug Farm raised $55 million for its ALPK1 inhibitors. MindRank AI also closed a $52 million round to further develop its drug discovery platform. Lastly, Alchemab Therapeutics extended its Series A financing with a $34 million investment aimed at expanding its antibody database and clinical pipeline.
The surge in funding across these companies reflects a growing investor confidence in innovative therapies and technologies, particularly in the realms of targeted treatments and AI-driven drug development, highlighting the dynamic nature of the life sciences sector.